<DOC>
	<DOCNO>NCT00752999</DOCNO>
	<brief_summary>Approximately 225 patient meet study entry requirement enrol randomize ( 2:1 , active versus placebo superimpose background treatment ) R788 placebo . Patients follow efficacy safety parameter 6 month . The investigator taper corticosteroid clinically warrant .</brief_summary>
	<brief_title>Efficacy Safety Study R935788 Tablets Treat Systemic Lupus Erythematosus</brief_title>
	<detailed_description>This study multi-center , multinational , randomize , double-blind , placebo-controlled Phase II clinical trial . Study enrollment comprise approximately 225 patient meet study inclusion requirement . The study conduct 80 multinational investigational site . Eligible patient randomize ( 2:1 ) one two 6 month treatment group . One group ( approximately 150 patient ) receive R788 150 mg PO bid ; treatment group ( approximately 75 patient ) receive placebo .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Patients must give write informed consent participate study sign IRB/ECapproved Informed Consent Form ( ICF ) prior admission study . Males female , 18 year age old , active SLE diagnose least 6 month prior Day 1 dosing . Active SLE define fulfil ACR criterion SLE . Patients childbearing potential must fully inform potential R788 adversely affect fetus , sexually active , must agree use effective method birth control study ( oral contraceptive , mechanical barrier , long act hormonal agent ) . The patient must otherwise good health determine investigator basis medical history , physical examination , laboratory screening test screen period . In investigator 's opinion , patient ability understand nature study anticipate risk participation , communicate satisfactorily investigator , participate comply requirement entire protocol . The patient history , concurrent , clinically significant illness , medical condition laboratory abnormality , investigator 's opinion , could affect conduct study . Clinically significant uncontrolled medical disease organ system , due SLE . Background immunosuppressive therapy remain stable â‰¤ 4 week prior baseline . Severe active unstable renal disease . Active severe neuropsychiatric SLE . Female patient must breastfeed must negative urine pregnancy test per Schedule Study Activities . The patient history substance abuse , drug addiction , alcoholism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
</DOC>